Adipotide Research: Prohibitin-Targeting Peptide in Obesity Models

Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.

Introduction

Adipotide is an experimental peptidomimetic that has been studied in preclinical obesity models for its ability to target the vasculature that supplies white adipose tissue. Rather than acting on appetite or systemic metabolic signaling, the compound was designed around a vascular homing strategy: a short targeting sequence that recognizes prohibitin, a membrane-associated protein reported on the endothelial cells lining blood vessels inside fat depots, joined to a pro-apoptotic sequence that becomes active only after the construct is internalized. This article summarizes what laboratory and animal-model research has described about adipotide and its studied molecular target.

Interest in adipotide within the research community comes from its unusual mechanism among the research peptides investigated in metabolic contexts. Where many metabolic research compounds engage receptors involved in cellular signaling, adipotide was engineered to concentrate at a tissue-specific vascular address and reduce the local blood supply that adipose tissue depends on. Everything described below reflects preclinical, in-vitro, and animal-model literature. It is presented for research use only, not for human consumption, and no human weight-loss, dosing, or efficacy conclusions are drawn.

What Is Adipotide?

Adipotide, also referenced by the research designation Prohibitin-TP01, is a chimeric peptide built from two functional modules connected by a short linker. The design pairs a vascular targeting motif with a membrane-disrupting effector, so that the effector portion is delivered preferentially to one defined tissue address instead of circulating broadly.

A Two-Domain Architecture

The first module is a nine-residue cyclic homing peptide, CKGGRAKDC, identified through phage-display screening as a ligand that concentrates in the vasculature of white adipose tissue. The second module is a synthetic pro-apoptotic sequence, D(KLAKLAK)2, composed of D-amino acids that resist enzymatic degradation. On its own the effector domain has limited access to the interior of cells, but when the homing domain docks it at the target endothelium the whole construct can be taken up. This modular logic (a targeting address plus a payload) is a recurring theme in the vascular-targeting literature.

The following identity values reflect commonly reported laboratory attributes and are provided for comparison only.

The Prohibitin-Targeting Mechanism

The rationale behind adipotide rests on the idea that fat tissue, like a tumor, depends on an expanding network of blood vessels to grow and persist. If those vessels display a distinctive surface marker, a peptide can be built to recognize that marker and deliver a signal specifically there. In adipotide, that marker is prohibitin.

The Homing Domain and Prohibitin

Prohibitin is a conserved protein with established roles in mitochondrial function and cell signaling. In the research that led to adipotide, it was also reported on the luminal surface of blood vessels feeding white adipose tissue, giving it the character of a vascular address code that distinguishes fat-tissue capillaries from those of many other organs. The CKGGRAKDC motif was selected for its affinity to this address, allowing the construct to accumulate where it is intended to act rather than spreading uniformly through the circulation.

The Pro-Apoptotic Domain

Once internalized, the D(KLAKLAK)2 sequence disrupts mitochondrial membranes, a process reported to trigger programmed cell death, or apoptosis, in the targeted endothelial cells. In animal models, the resulting regression of adipose capillaries was associated with resorption of the surrounding fat tissue over time. It is important to frame this precisely: these are observations from controlled laboratory and animal research into a mechanism, not statements about human outcomes. The same D(KLAKLAK)2 effector has appeared in earlier targeted-peptide research aimed at other vascular beds, which is part of why its behavior is comparatively well characterized in vitro.

Adipotide in Preclinical Obesity Models

The published adipotide literature is built on animal-model work, and reading it correctly means keeping that scope in view. The studies describe how a targeted peptide behaves in defined organisms under controlled conditions, and they inform hypotheses rather than clinical practice.

Rodent Studies

The foundational work by Kolonin, Arap, and Pasqualini (Nature Medicine, 2004) introduced the concept of ablating adipose tissue by targeting its blood supply in mouse models. That research established prohibitin as a candidate vascular marker of white fat and demonstrated the homing-plus-effector design in a controlled rodent setting. It is the reference point from which later adipotide studies developed.

Non-Human Primate Studies

Subsequent research reported by Barnhart and colleagues (Science Translational Medicine, 2011) examined the prohibitin-targeting peptidomimetic in obese non-human primates, a model considered physiologically closer to human biology than rodents. The primate work is frequently cited because it extended the vascular-targeting concept into a more complex organism while also documenting reversible effects on renal tissue observed under study conditions. These findings are described here strictly as animal-model research observations. No inference is made about human safety, tolerability, or benefit, and adipotide is not characterized as a treatment for any condition.

Research Context and Where Adipotide Fits

Adipotide is discussed on this page for scientific context and is not part of the Rejuven8 catalog. Placing it alongside metabolic research peptides that are stocked helps clarify how different mechanistic categories are studied. The compounds below occupy distinct mechanistic niches: adipotide is a vascular-homing, pro-apoptotic construct, while the catalog examples are studied through receptor-signaling or metabolic-signaling pathways.

The values below reflect commonly reported laboratory attributes and are provided for comparison only.

Because adipotide itself is a research construct rather than a stocked product, the practical takeaways for laboratory buyers are about sourcing standards generally. Anyone evaluating metabolic research peptides should confirm identity and purity documentation before use. Reviewing a supplier’s certificates of analysis, learning how to read a peptide COA, and applying a structured approach to choosing a research peptide supplier are the steps that keep experimental records defensible and reproducible.

Frequently Asked Questions

What is adipotide and how does it work in research models?

Adipotide is a chimeric peptidomimetic studied in preclinical obesity models. It combines a homing sequence that recognizes prohibitin on the vasculature of white adipose tissue with a pro-apoptotic sequence that, once internalized, disrupts mitochondrial membranes in the targeted endothelial cells. In animal studies this was associated with regression of adipose capillaries.

What is prohibitin and why is it an adipotide target?

Prohibitin is a membrane-associated protein with roles in mitochondrial biology. Research identified it on the surface of blood vessels supplying white adipose tissue, where it can act as a tissue-selective vascular marker. Adipotide’s homing domain was selected to bind this marker so the construct concentrates in fat-tissue vasculature.

Has adipotide been studied in humans?

The most cited adipotide research involves animal models, including rodents and obese non-human primates. This overview is limited to that preclinical and animal-model literature and makes no claims about human use, safety, or efficacy.

What is the D(KLAKLAK)2 domain in adipotide?

D(KLAKLAK)2 is a synthetic pro-apoptotic peptide made of D-amino acids that resist enzymatic breakdown. It disrupts mitochondrial membranes when it reaches the interior of a cell, and in adipotide it serves as the effector delivered by the prohibitin-homing domain.

Is adipotide available as a research peptide from Rejuven8?

No. Adipotide is discussed here for scientific context only and is not part of the Rejuven8 catalog. Researchers interested in metabolic-pathway compounds can review the lab-tested options in the research peptide shop.

How does adipotide differ from GLP metabolic research peptides?

GLP-class research peptides are studied for their interaction with incretin receptors involved in metabolic signaling. Adipotide instead uses a vascular-targeting, pro-apoptotic mechanism aimed at the blood supply of fat tissue, which places it in a distinct mechanistic category.

References and Further Reading

1. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue in mouse models. Nature Medicine, 2004. PubMed: targeted ablation adipose tissue prohibitin
2. Barnhart KF and colleagues. Study of a prohibitin-targeting peptidomimetic in obese non-human primates. Science Translational Medicine, 2011. PubMed: adipotide prohibitin primate
3. Prohibitin as a candidate vascular marker of white adipose tissue. PubMed: prohibitin adipose vasculature
4. Ellerby HM, Arap W, Pasqualini R and colleagues. Anti-cancer activity of targeted pro-apoptotic peptides using the D(KLAKLAK)2 effector. Nature Medicine, 1999. PubMed: targeted pro-apoptotic peptide KLAKLAK
5. Homing peptides and phage-display selection against vascular targets. PubMed: homing peptide phage display vasculature
6. Angiogenesis of white adipose tissue in obesity research. PubMed: adipose tissue angiogenesis obesity
7. Peptidomimetic vascular-targeting strategies in metabolic research. PubMed: vascular targeting peptide adipose